Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
INZY Stock Forecast 2025-2026
$4.00
Current Price
$258.25M
Market Cap
Buy 0
Hold 6
Sell 0
Wall St Analyst Ratings
Distance to INZY Price Targets
0.0%
To High Target of $4.00
0.0%
To Median Target of $4.00
0.0%
To Low Target of $4.00
INZY Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
+55.6%
1 Year Change
+44.4%
Year-to-Date Change
-35.9%
From 52W High of $6.24
+454.8%
From 52W Low of $0.72
📊 TOP ANALYST CALLS
Did INZY Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Inozyme is one of their latest high-conviction picks.
Latest INZY Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, INZY has a neutral consensus with a median price target of $4.00 (ranging from $4.00 to $4.00). The overall analyst rating is Buy (6.0/10). Currently trading at $4.00, the median forecast implies a 0.0% downside. This outlook is supported by 0 Buy, 6 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Ryan Deschner at Jefferies, projecting a 0.0% downside. Conversely, the most conservative target is provided by Ryan Deschner at Jefferies, suggesting a 0.0% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
INZY Analyst Ratings
0
Buy
6
Hold
0
Sell
INZY Price Target Range
Low
$4.00
Average
$4.00
High
$4.00
Current: $4.00
Latest INZY Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for INZY.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 16, 2025 | Jefferies | Ryan Deschner | Hold | Downgrade | $4.00 |
| May 16, 2025 | Wells Fargo | Tiago Fauth | Equal-Weight | Downgrade | $4.00 |
| May 16, 2025 | Needham | Joseph Stringer | Hold | Downgrade | $12.00 |
| May 14, 2025 | Needham | Joseph Stringer | Buy | Maintains | $12.00 |
| Apr 10, 2025 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $16.00 |
| Apr 8, 2025 | Needham | Joseph Stringer | Buy | Reiterates | $15.00 |
| Mar 12, 2025 | Raymond James | Ryan Deschner | Outperform | Maintains | $12.00 |
| Mar 11, 2025 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $16.00 |
| Mar 11, 2025 | Needham | Joseph Stringer | Buy | Maintains | $15.00 |
| Mar 11, 2025 | Piper Sandler | Allison Bratzel | Overweight | Maintains | $23.00 |
| Jan 13, 2025 | Piper Sandler | Christopher Raymond | Overweight | Maintains | $30.00 |
| Jan 13, 2025 | HC Wainwright & Co. | Edward White | Buy | Maintains | $16.00 |
| Jan 13, 2025 | Wells Fargo | Tiago Fauth | Overweight | Maintains | $11.00 |
| Jan 10, 2025 | HC Wainwright & Co. | Edward White | Buy | Maintains | $16.00 |
| Nov 6, 2024 | Needham | Joseph Stringer | Buy | Reiterates | $23.00 |
| Nov 6, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $14.00 |
| Oct 25, 2024 | Needham | Joseph Stringer | Buy | Reiterates | $23.00 |
| Oct 25, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $14.00 |
| Sep 30, 2024 | Wedbush | David Nierengarten | Outperform | Reiterates | $15.00 |
| Sep 12, 2024 | Stifel | Dae Gon Ha | Buy | Initiates | $16.00 |
Inozyme Pharma, Inc. (INZY) Competitors
The following stocks are similar to Inozyme based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Inozyme Pharma, Inc. (INZY) Financial Data
Valuation Metrics
Market Cap
$258.25M
Enterprise Value
$220.43M
P/E Ratio
N/A
PEG Ratio
-2.5x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+32.8%
Current Ratio
2.2x
Debt/Equity
147.7x
ROE
-141.7%
ROA
-48.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Inozyme Pharma, Inc. (INZY) Business Model
About Inozyme Pharma, Inc.
What They Do
Develops therapies for rare mineralization disorders.
Business Model
Inozyme Pharma generates revenue by developing novel enzyme replacement therapies aimed at treating rare mineralization disorders. The company focuses on diseases with limited treatment options, leveraging its expertise in mineralization biology to create targeted therapies that address the root causes of these conditions.
Additional Information
By targeting diseases like generalized arterial calcification of infancy and autosomal recessive hypophosphatemic rickets type 2, Inozyme Pharma is positioned to meet significant unmet medical needs. Their research-driven approach and commitment to innovation underscore their potential to enhance patient outcomes and quality of life.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
67
CEO
Dr. Douglas A. Treco Ph.D.
Country
United States
IPO Year
2020
Website
www.inozyme.comInozyme Pharma, Inc. (INZY) Latest News & Analysis
Latest News
Quick Summary
BioMarin's Q2 2025 revenue rose 16% YoY, with full-year guidance raised to $3.125–$3.2 billion. The Inozyme acquisition adds BMN 401, with pivotal data expected in 1H 2026. Voxzogo and Palynziq drive growth.
Why It Matters
BioMarin's strong revenue growth and raised guidance signal robust financial health. The Inozyme acquisition and promising pipeline enhance its competitive positioning, likely boosting stock value.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
BioMarin Pharmaceutical Inc. has completed its acquisition of Inozyme Pharma for $4.00 per share, totaling approximately $270 million.
Why It Matters
BioMarin's acquisition of Inozyme for $270 million may enhance its product pipeline and market position, potentially impacting future earnings and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Inozyme Pharma has postponed its 2025 Annual Meeting, originally set for June 25, due to its acquisition by BioMarin Pharmaceutical.
Why It Matters
The postponement of Inozyme Pharma's annual meeting signals significant developments related to the acquisition by BioMarin, potentially impacting stockholder decisions and company valuation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Kahn Swick & Foti is investigating the proposed sale of Inozyme Pharma (INZY) to BioMarin Pharmaceutical (BMRN), where Inozyme shareholders would receive $4.00 per share.
Why It Matters
The investigation into Inozyme Pharma's sale to BioMarin may indicate potential undervaluation or irregularities, impacting shareholder sentiment and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Inozyme Pharma, Inc. - INZY
6 months ago
Quick Summary
Monteverde & Associates is investigating Inozyme Pharma's proposed merger with BioMarin, which plans to acquire Inozyme shares at $4.00 each.
Why It Matters
The investigation into Inozyme Pharma's merger with BioMarin could impact stock valuations and shareholder returns, signaling potential legal risks or issues in the acquisition process.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
The Ademi Firm is investigating Inozyme (Nasdaq: INZY) for potential fiduciary duty breaches related to its deal with BioMarin, which offers $4.00 per share in cash to shareholders.
Why It Matters
The investigation into Inozyme's transaction with BioMarin raises concerns about potential legal issues and fiduciary breaches, possibly impacting share value and investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About INZY Stock
What is Inozyme Pharma, Inc.'s (INZY) stock forecast for 2026?
Based on our analysis of 12 Wall Street analysts, Inozyme Pharma, Inc. (INZY) has a median price target of $4.00. The highest price target is $4.00 and the lowest is $4.00.
Is INZY stock a good investment in 2026?
According to current analyst ratings, INZY has 0 Buy ratings, 6 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.00. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for INZY stock?
Wall Street analysts predict INZY stock could reach $4.00 in the next 12 months. This represents a 0.0% decrease from the current price of $4.00. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Inozyme Pharma, Inc.'s business model?
Inozyme Pharma generates revenue by developing novel enzyme replacement therapies aimed at treating rare mineralization disorders. The company focuses on diseases with limited treatment options, leveraging its expertise in mineralization biology to create targeted therapies that address the root causes of these conditions.
What is the highest forecasted price for INZY Inozyme Pharma, Inc.?
The highest price target for INZY is $4.00 from Ryan Deschner at Jefferies, which represents a 0.0% decrease from the current price of $4.00.
What is the lowest forecasted price for INZY Inozyme Pharma, Inc.?
The lowest price target for INZY is $4.00 from Ryan Deschner at Jefferies, which represents a 0.0% decrease from the current price of $4.00.
What is the overall INZY consensus from analysts for Inozyme Pharma, Inc.?
The overall analyst consensus for INZY is neutral. Out of 12 Wall Street analysts, 0 rate it as Buy, 6 as Hold, and 0 as Sell, with a median price target of $4.00.
How accurate are INZY stock price projections?
Stock price projections, including those for Inozyme Pharma, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 5:12 PM UTC